The global direct-to-consumer genetic testing market is expected to reach $310 million in 2022, according to a Kalorama Information report released Jan. 10.
For the report, the biotechnology and in-vitro diagnostics market research firm reviewed information from leading industry companies and research papers published in medical and business journals. Kalorama Information analysts also conducted interviews with industry officials, consultants, providers and government personnel.
Here are four things to know about the direct-to-consumer genetic testing market.
1. The global direct-to-consumer genetic testing market totaled $99 million in 2017. The market is expected to experience 25.6 percent growth, reaching $310 million in 2022.
2. The market's primary growth driver is patient interest in gaining greater control over their healthcare. Another relevant trend is growing interest in early disease detection and personalized medicine.
3. One barrier to the market's growth is uncertainty of how patients interpret and use test results. To address this concern, many companies connect customers with on-site or remote genetic counselors.
4. An area to watch in the direct-to-consumer genetic testing market is regulatory oversight, which will likely become less stringent during the forecast period, according to Kalorama Information analysts. The industry experienced a milestone in April when the FDA approved 23andMe to market at-home genetic tests for 10 diseases.